刘晓宇;马锐;胡伟军;高宇畅;侯绪光;王辉;张少白;

• 1:陕西省疾病预防控制中心
• 2:北京生物制品研究所有限责任公司

摘要(Abstract)：

目的分析2018—2020年陕西省Sabin株脊髓灰质炎灭活疫苗[inactivated poliomyelitis vaccine prepared from Sabin strain(Vero cells),sIPV]疑似预防接种异常反应(adverse event following immunization,AEFI)的发生情况。方法通过AEFI监测信息管理系统收集陕西省2018年1月1日—2020年5月6日sIPV监测数据,采用描述性流行病学方法进行分析。结果陕西省2018年1月1日—2020年5月6日共报告sIPV的AEFI病例141例,报告发生率为34.24/10万,其中一般反应报告发生率为32.29/10万,异常反应报告发生率为1.46/10万。一般反应以发热(占比42.68%)、婴儿哭闹(占比18.41%)、疫苗接种部位肿胀(占比12.97%)为主,异常反应以过敏性皮疹(占比42.86%)为主。无严重AEFI病例报告,AEFI病例总体转归情况良好。结论 sIPV具有良好的安全性,AEFI以一般反应为主。

关键词(KeyWords)： 脊髓灰质炎灭活疫苗;疑似预防接种异常反应;安全性

Abstract:

Keywords:

基金项目(Foundation): “重大新药创制”科技重大专项（2018ZX09737003）

作者(Authors): 刘晓宇;马锐;胡伟军;高宇畅;侯绪光;王辉;张少白;

DOI: 10.13200/j.cnki.cjb.003451

参考文献(References)：

• [1]General Office of Ministry of Health,General Office of State Food and Drug Administration.National guideline for surveillance of adverse events following immunization[S].2010-06-10.(in Chinese）卫生部办公厅，国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[S].2010-06-10.
• [2]CLOTHIER H J,LAWRIE J,LEWIS G,et al.SAEFVIC:Surveillance of adverse events following immunization (AEFI)in Victoria,Australia,2018[J].Commun Dis Intellig,2018,2020:44.
• [3]LIU Y,XU Y Y,WANG J,et al.Vaccination pattern of the23-valent pneumococcal polysaccharide vaccine(PPV23)in Hangzhou,China:a coverage and adverse events following immunization of different age groups[J].Hum Vaccin&Immunother,2020(1):1-5.
• [4]TANG G H,YIN W,CAO Y D,et al.Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV)versus inactivated poliovirus vaccine(IPV) alone in healthy infants:Asystematic review and meta-analysis[J].Hum Vaccin&Immunother,2018,14(11):2636-2643.
• [5]HU Y M,WANG J F,ZENG G,et al.Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine:A phase 3 clinical trial[J].J Infect Dis,2019,220(10):1551-1557.
• [6]National Health and Family Planning Commission.China implements a new polio vaccine immunization strategy according to the WHO resolution[EB/OL].(2016-04-29)[2020-11-06].http：//www.nhc.gov.cn/jkj/s3582/201604/8c760a934d5b4-d41a81752915c58d304.shtml.(in Chinese）国家卫生计生委.我国响应世卫组织决议实施脊灰疫苗免疫新策略[EB/OL].(2016-04-29)[2020-11-06].http：//www.nhc.gov.cn/jkj/s3582/201604/8c760a934d5b4d41a81752-915c58d304.shtml.
• [7]JORBA J,DIOP O M,IBER J,et al.Update on vaccine-derived poliovirus outbreaks-worldwide,January 2018-June 2019[J].MMWR,2019,68(45):1024-1028.
• [8]中华人民共和国国家卫生健康委员会.关于国家免疫规划脊髓灰质炎疫苗和含麻疹成分疫苗免疫程序调整相关工作的通知.国卫疾控发[2019]65号.（2020-01-07)[2020-11-06].http：//www.nhc.gov.cn/jkj/s3589/202001/ba151e4ad7824-ad6950d8d24879a2235.shtml.
• [9]DIXON B.Medicine and the media:polio still paralyses(Albert Sabin,Jonas Salk)[J].Brit J Hosp Med,1977,18(6):595.
• [10]XAVIER S L,BIRGIT T C,LINA S S,et al.Immunogenicity and safety of an adjuvanted inactivated polio vaccine,IPV-Al,following vaccination in children at 2,4,6 and at 15-18 months[J].Vaccine,2020,38(21):3780-3789.
• [11]Global Polio Eradication Initiative.Wild poliovirus list.2019[EB/OL].(2020-01-31)[2020-11-06].http：//polioeradication.org/polio-today/polio-now/wild-poliovirus-list/.
• [12]GURUNG S,HARRIS J B,ELTAYEB A O,et al.Experience with inactivated polio vaccine introduction and the“switch”from trivalent to bivalent oral polio vaccine in the World Health Organization′s Western Pacific region[J].J Infect Dis,2017,216(suppl 1):S101-108.
• [13]CHU K,YING Z F,WANG L,et al.Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains:Aphase II,randomized,dose-finding trial[J].Vaccine,2018,36(45):6782-6789.
• [14]BANDYOPADHYAY A S,GARON J,SEIB K,et al.Polio vaccination:past,present and future[J].Future Microbiol,2015,10(5):791-808.
• [15]LI K L,ZHANG L N,YE J K,et al.Adverse events following immunization in China,2016[J].Chin J Vaccin Immun,2020,26(1):9-18.(in Chinese）李克莉，张丽娜，叶家楷，等.中国2017年疑似预防接种异常反应监测[J].中国疫苗和免疫，2020,26(1):9-18.
• [16]TANG X W,WANG Y,DENG X,et al.Surveillance of adverse events following immunization with poliomyelitis vaccines in Zhejiang province,2017[J].Chin J Vaccin Immun,2019,25(2):211-214.(in Chinese）唐学雯，汪颖，邓璇，等.浙江省2017年脊髓灰质炎疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫，2019,25(2):211-214.
• [17]ZHENG M,WU F Y,ZHAO H P,et al.Adverse events following immunization for poliomyelitis vaccine in Jiangxi province,2017-2018[J].Modern Prevent Med,2019,46(23):4382-4385.(in Chinese）郑敏，伍凤云，赵红平，等.2017-2018年江西省脊髓灰质炎疫苗疑似预防接种异常反应监测分析[J].现代预防医学，2019,46(23):4382-4385.
• [18]SUN L,ZHANG F B,WANG L N,et al.Monitoring adverse events following immunization with poliomyelitis vaccines in Hebei province[J].Chin J Vaccin Immun,2017,23 (5):498-502.(in Chinese）孙丽，张富斌，王丽娜，等.河北省脊髓灰质炎疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫，2017,23(5):498-502.
• [19]HE H,WANG Y,DENG X,et al.Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang,China:an openlabel,randomised,controlled trial[J].Lancet Infect Dis,2020,20(9):1071-1079.
• [20]STANLEY A P,WALTER A O,PAUL A O.疫苗学[M].北京：人民卫生出版社，2011:867-903.
• [21]DENG P F,FEI Y,YANG T,et al.Progress in research on immune efficacy and safety of various sequential immunization schedules of poliomyelitis vaccine in China[J].Chin J Biologicals,2019,32(7):823-827.(in Chinese）邓鹏飞，费怡，杨天，等.国内脊髓灰质炎疫苗不同序贯免疫程序免疫效果及安全性的研究进展[J].中国生物制品学杂志，2019,32(7):823-827.